SG11201906933SA - Functionalized erythroid cells - Google Patents
Functionalized erythroid cellsInfo
- Publication number
- SG11201906933SA SG11201906933SA SG11201906933SA SG11201906933SA SG11201906933SA SG 11201906933S A SG11201906933S A SG 11201906933SA SG 11201906933S A SG11201906933S A SG 11201906933SA SG 11201906933S A SG11201906933S A SG 11201906933SA SG 11201906933S A SG11201906933S A SG 11201906933SA
- Authority
- SG
- Singapore
- Prior art keywords
- suite
- cambridge
- vassar
- international
- rule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
Abstract
Substratereactive moiety \ Click handle 1 Click handle 2 /agen t\ Coupling reagent 1 Coupling reagent 2 Click handle 2 Click handle 1 Substrate-reactive moiety 1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WI P0 I PC T limion omits onolomolu onolomiomom (10) International Publication Number WO 2018/151829 Al (51) International Patent Classification: C12N 5/078 (2010.01) (21) International Application Number: PCT/US2018/000042 (22) International Filing Date: 16 February 2018 (16.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/460,589 17 February 2017 (17.02.2017) US 62/542,142 07 August 2017 (07.08.2017) US (71) Applicant: RUBIUS THERAPEUTICS, INC. [US/US]; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). (72) Inventors: WICKHAM, Tom; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). CHEN, Tiffany, F.; 325 Vas- sar St Suite 1A, Cambridge, MA 02139 (US). ZHANG, Xuqing; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). HUDAK, Carolyn; 325 Vassar St Suite 1A, Cam- bridge, MA 02139 (US). MATA-FINK, Jordi; 325 Vas- sar St Suite 1A, Cambridge, MA 02139 (US). ELLOUL, Sivan; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). LAW, Billy; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). HOFFMAN, Lenka; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). TEICHERT, Kristian, Eric; 325 Vassar St Suite 1A, Cambridge, MA 02139 (US). DAS- TAGIR, Shamael, Rabia; 325 Vassar St Suite 1A, Cam- bridge, MA 02139 (US). (74) Agent: YANG, Peter et al.; Lando & Anastasi, LLP, River- front Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — (54) Title: FUNCTIONALIZED ERYTHROID CELLS 1111 A Click srt s ure FIG. 1 0 (57) : Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods \" for use in human pharmaceutical and veterinary applications. C [Continued on next page] WO 2018/151829 Al MIDEDIMOMOIDEIREEM311011111010MODEVOIS UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762460589P | 2017-02-17 | 2017-02-17 | |
US201762542142P | 2017-08-07 | 2017-08-07 | |
PCT/US2018/000042 WO2018151829A1 (en) | 2017-02-17 | 2018-02-16 | Functionalized erythroid cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906933SA true SG11201906933SA (en) | 2019-09-27 |
Family
ID=61873874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906933SA SG11201906933SA (en) | 2017-02-17 | 2018-02-16 | Functionalized erythroid cells |
Country Status (12)
Country | Link |
---|---|
US (2) | US11020435B2 (en) |
EP (1) | EP3583202A1 (en) |
JP (1) | JP2020507329A (en) |
KR (1) | KR20190117667A (en) |
CN (1) | CN110520522A (en) |
AU (1) | AU2018221227A1 (en) |
BR (1) | BR112019016951A2 (en) |
CA (1) | CA3052142A1 (en) |
IL (1) | IL268359A (en) |
MX (1) | MX2019009839A (en) |
SG (1) | SG11201906933SA (en) |
WO (1) | WO2018151829A1 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016011195A2 (en) | 2013-11-18 | 2017-09-19 | Rubius Therapeutics Inc | ENUCLEATED ERYTHROID CELLS AND THEIR METHODS OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND THEIR USE, USE OF AN ERYTHROID CELL POPULATION, BIORACTOR, CELL MIXTURE AND MEDICAL DEVICE |
HUE054471T2 (en) | 2014-04-01 | 2021-09-28 | Rubius Therapeutics Inc | Methods and compositions for immunomodulation |
CN108778298A (en) | 2016-01-11 | 2018-11-09 | 鲁比厄斯治疗法股份有限公司 | Composition related with the multi-mode therapeutic cells system of immunological adaptation disease and method |
US11020435B2 (en) * | 2017-02-17 | 2021-06-01 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
WO2019090148A2 (en) | 2017-11-03 | 2019-05-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
KR20200104887A (en) * | 2017-12-23 | 2020-09-04 | 루비우스 테라퓨틱스, 아이엔씨. | Artificial antigen presenting cells and methods of use |
US20190330591A1 (en) | 2018-01-10 | 2019-10-31 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
SG11202008261WA (en) | 2018-03-08 | 2020-09-29 | Rubius Therapeutics Inc | Therapeutic cell systems and methods for treating cancer and infectious diseases |
US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
CA3125567A1 (en) | 2019-01-18 | 2020-07-23 | Flagship Pioneering, Inc. | Trem compositions and uses thereof |
BR112021016451A2 (en) | 2019-02-20 | 2021-11-09 | Rubius Therapeutics Inc | Engineered erythroid cell including chargeable antigen-presenting polypeptides and methods of use |
CA3128626A1 (en) | 2019-03-04 | 2020-09-10 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides and pharmaceutical compositions thereof |
KR20210142678A (en) | 2019-03-25 | 2021-11-25 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | Compositions comprising modified circular polyribonucleotides and uses thereof |
CN114269921A (en) | 2019-05-31 | 2022-04-01 | 旗舰创业股份有限公司 | Use of TREM compositions to modulate tRNA cells |
JP2022537154A (en) | 2019-06-14 | 2022-08-24 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | circular RNA for cell therapy |
WO2020257730A1 (en) | 2019-06-19 | 2020-12-24 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
US20220364075A1 (en) | 2019-11-04 | 2022-11-17 | Flagship Pioneering, Inc. | Methods of modifying a nucleic acid sequence |
US20220364092A1 (en) | 2019-11-04 | 2022-11-17 | Flagship Pioneering, Inc. | Trem compositions for con-rare codons and related uses |
US20230340451A1 (en) | 2020-01-29 | 2023-10-26 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising linear polyribonucleotides for protein modulation and uses thereof |
TW202142689A (en) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | Compositions for translation and methods of use thereof |
TW202142239A (en) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | Delivery of compositions comprising circular polyribonucleotides |
WO2021162731A1 (en) | 2020-02-10 | 2021-08-19 | Rubius Therapeutics, Inc. | Engineered erythroid cells including hla-g polypeptides and methods of use thereof |
CN115335064A (en) * | 2020-03-20 | 2022-11-11 | 西湖生物医药科技(杭州)有限公司 | Modified red blood cells and their use for delivery of agents |
WO2021236980A1 (en) | 2020-05-20 | 2021-11-25 | Flagship Pioneering Innovations Vi, Llc | Coronavirus antigen compositions and their uses |
WO2021236952A1 (en) | 2020-05-20 | 2021-11-25 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
CN116194139A (en) | 2020-05-20 | 2023-05-30 | 旗舰创业创新第六有限责任公司 | Immunogenic compositions and uses thereof |
WO2021243301A2 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
CN116018405A (en) | 2020-05-29 | 2023-04-25 | 旗舰先锋创新Vi有限责任公司 | TREM compositions and related methods |
EP4167984A1 (en) | 2020-06-23 | 2023-04-26 | Flagship Pioneering, Inc. | Anti-viral compounds and methods of using same |
EP4208196A1 (en) | 2020-09-03 | 2023-07-12 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
CA3206285A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
CN117730143A (en) * | 2021-07-13 | 2024-03-19 | 西湖生物医药科技(杭州)有限公司 | Cells modified by conjugated N-terminal glycine and uses thereof |
WO2023009547A1 (en) | 2021-07-26 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
AU2022346861A1 (en) | 2021-09-17 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
TW202322826A (en) | 2021-10-18 | 2023-06-16 | 美商旗艦先鋒創新有限責任公司 | Compositions and methods for purifying polyribonucleotides |
WO2023097003A2 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and their uses |
WO2023096963A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
WO2023096990A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovation Vi, Llc | Coronavirus immunogen compositions and their uses |
TW202340461A (en) | 2021-12-22 | 2023-10-16 | 美商旗艦先鋒創新有限責任公司 | Compositions and methods for purifying polyribonucleotides |
TW202342064A (en) | 2021-12-23 | 2023-11-01 | 美商旗艦先鋒創新有限責任公司 | Circular polyribonucleotides encoding antifusogenic polypeptides |
WO2023196593A1 (en) * | 2022-04-08 | 2023-10-12 | The University Of North Carolina At Chapel Hill | Antigen-independent targeted delivery of therapeutic agents |
WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
WO2023220729A2 (en) | 2022-05-13 | 2023-11-16 | Flagship Pioneering Innovations Vii, Llc | Double stranded dna compositions and related methods |
WO2023230549A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of tumor suppressors and oncogenes |
WO2023230566A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating cytokines |
WO2023230573A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of immune responses |
WO2023230578A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating circulating factors |
WO2023230570A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating genetic drivers |
WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
WO2024102799A1 (en) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070243137A1 (en) | 2006-04-18 | 2007-10-18 | Nanoprobes, Inc. | Cell and sub-cell methods for imaging and therapy |
US8501478B2 (en) | 2006-06-15 | 2013-08-06 | University Of Cincinnati | Trehalose click polymers for delivery of biologically active molecules |
KR20090094812A (en) | 2006-10-18 | 2009-09-08 | 더 스크립스 리서치 인스티튜트 | Genetic incorporation of unnatural amino acids into proteins in mammalian cells |
EP2057998A1 (en) | 2007-10-31 | 2009-05-13 | Universitätsklinikum Hamburg-Eppendorf | Use of modified cells for the treatment of multiple sclerosis |
US20110086424A1 (en) * | 2008-05-06 | 2011-04-14 | Advanced Cell Technology, Inc. | Methods for producing enucleated erythroid cells derived from pluripotent stem cells |
US20100040546A1 (en) | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
US20120034156A1 (en) | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
CA2753189A1 (en) | 2009-02-21 | 2010-08-26 | Nadya Belcheva | Medical devices having activated surfaces |
WO2011059586A2 (en) | 2009-10-30 | 2011-05-19 | The Regents Of The University Of Michigan | Multifunctional small molecules |
CA2758390A1 (en) * | 2011-11-14 | 2013-05-14 | Ibc Pharmaceuticals, Inc. | Stem cell targeting with dock-and-lock (dnl) complexes |
AU2013203832B2 (en) | 2012-03-13 | 2016-09-15 | Celularity Inc. | Modified erythrocyte precursor cells and uses thereof |
FR2997082B1 (en) | 2012-10-18 | 2015-02-13 | Centre Nat Rech Scient | MULTIFUNCTIONAL COUPLING REAGENTS WITH AZLACTONE FUNCTION. |
US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
ES2901383T3 (en) | 2013-05-10 | 2022-03-22 | Whitehead Inst Biomedical Res | In vitro production of red blood cells with sortase-markable proteins |
JP2015032986A (en) | 2013-08-02 | 2015-02-16 | 住友電気工業株式会社 | Radio terminal device, radio base station device, communication system, radio access providing method, and communication control program |
BR112016011195A2 (en) | 2013-11-18 | 2017-09-19 | Rubius Therapeutics Inc | ENUCLEATED ERYTHROID CELLS AND THEIR METHODS OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND THEIR USE, USE OF AN ERYTHROID CELL POPULATION, BIORACTOR, CELL MIXTURE AND MEDICAL DEVICE |
HUE054471T2 (en) | 2014-04-01 | 2021-09-28 | Rubius Therapeutics Inc | Methods and compositions for immunomodulation |
US10053683B2 (en) | 2014-10-03 | 2018-08-21 | Whitehead Institute For Biomedical Research | Intercellular labeling of ligand-receptor interactions |
US20180110831A1 (en) | 2015-03-09 | 2018-04-26 | Stc.Unm | Cd 47 containing porous nanoparticle supported lipid bilayers (protocells) field of the invention |
WO2016183482A1 (en) | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
CN108778298A (en) * | 2016-01-11 | 2018-11-09 | 鲁比厄斯治疗法股份有限公司 | Composition related with the multi-mode therapeutic cells system of immunological adaptation disease and method |
WO2017152077A1 (en) | 2016-03-04 | 2017-09-08 | Whitehead Institute For Biomedical Research | Efficient generation of human red blood cells via enriching peripheral blood erythroid progenitors |
BR112019000195A2 (en) | 2016-07-07 | 2019-04-24 | Rubius Therapeutics, Inc. | compositions and methods related to therapeutic cellular systems expressing exogenous rna |
CN110225756A (en) * | 2016-12-02 | 2019-09-10 | 鲁比厄斯治疗法股份有限公司 | Composition relevant to the cell system for penetrating solid tumor and method |
US11020435B2 (en) * | 2017-02-17 | 2021-06-01 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
EP3672602A1 (en) * | 2017-08-22 | 2020-07-01 | Rubius Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
WO2019090148A2 (en) | 2017-11-03 | 2019-05-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
US20190201548A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for engineering erythroid cells |
US20190330591A1 (en) | 2018-01-10 | 2019-10-31 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
AU2019394875A1 (en) * | 2018-12-03 | 2021-06-17 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells including HLA-E and HLA-G molecules and methods of use |
BR112021016451A2 (en) * | 2019-02-20 | 2021-11-09 | Rubius Therapeutics Inc | Engineered erythroid cell including chargeable antigen-presenting polypeptides and methods of use |
CN114007627A (en) * | 2019-04-26 | 2022-02-01 | 鲁比厄斯治疗法股份有限公司 | Buffered compositions comprising enucleated erythroid cells |
WO2020243006A1 (en) * | 2019-05-24 | 2020-12-03 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells |
WO2021162731A1 (en) * | 2020-02-10 | 2021-08-19 | Rubius Therapeutics, Inc. | Engineered erythroid cells including hla-g polypeptides and methods of use thereof |
-
2018
- 2018-02-16 US US15/932,341 patent/US11020435B2/en active Active
- 2018-02-16 JP JP2019544032A patent/JP2020507329A/en not_active Ceased
- 2018-02-16 MX MX2019009839A patent/MX2019009839A/en unknown
- 2018-02-16 BR BR112019016951-2A patent/BR112019016951A2/en not_active IP Right Cessation
- 2018-02-16 EP EP18715274.9A patent/EP3583202A1/en not_active Withdrawn
- 2018-02-16 CN CN201880011595.7A patent/CN110520522A/en active Pending
- 2018-02-16 KR KR1020197027048A patent/KR20190117667A/en active Search and Examination
- 2018-02-16 SG SG11201906933SA patent/SG11201906933SA/en unknown
- 2018-02-16 WO PCT/US2018/000042 patent/WO2018151829A1/en unknown
- 2018-02-16 CA CA3052142A patent/CA3052142A1/en active Pending
- 2018-02-16 AU AU2018221227A patent/AU2018221227A1/en not_active Withdrawn
-
2019
- 2019-07-30 IL IL268359A patent/IL268359A/en unknown
-
2021
- 2021-05-27 US US17/331,884 patent/US20210290682A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2019129088A (en) | 2021-03-17 |
WO2018151829A1 (en) | 2018-08-23 |
RU2019129088A3 (en) | 2021-03-25 |
AU2018221227A1 (en) | 2019-08-15 |
CN110520522A (en) | 2019-11-29 |
JP2020507329A (en) | 2020-03-12 |
EP3583202A1 (en) | 2019-12-25 |
US11020435B2 (en) | 2021-06-01 |
BR112019016951A2 (en) | 2020-05-26 |
US20210290682A1 (en) | 2021-09-23 |
US20180344770A1 (en) | 2018-12-06 |
KR20190117667A (en) | 2019-10-16 |
MX2019009839A (en) | 2019-10-22 |
IL268359A (en) | 2019-09-26 |
CA3052142A1 (en) | 2018-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906933SA (en) | Functionalized erythroid cells | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
SG11201907653QA (en) | Compositions and methods for enhanced gene expression | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201811405QA (en) | Improved differentiation method | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201805137XA (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
SG11201909728XA (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201809872TA (en) | Using hardware based secure isolated region to prevent piracy and cheating on electronic devices | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201907434RA (en) | Compositions and methods for immunooncology | |
SG11201810872UA (en) | Composition and method for reducing neutropenia | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
SG11201900609PA (en) | Method and system for providing buffer solutions |